References
1. de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: From Biology to Clinical Management. J Clin Med . Jan 9 2015;4(1):127-49. doi:10.3390/jcm4010127
2. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood . Oct 18 2012;120(16):3187-205. doi:10.1182/blood-2012-03-362608
3. Shallis RM, Gale RP, Lazarus HM, et al. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Rev . May 2021;47:100773. doi:10.1016/j.blre.2020.100773
4. Zorn KE, Cunningham AM, Meyer AE, Carlson KS, Rao S. Pediatric Myeloid Sarcoma, More than Just a Chloroma: A Review of Clinical Presentations, Significance, and Biology. Cancers (Basel) . Feb 24 2023;15(5)doi:10.3390/cancers15051443
5. Eckardt JN, Stolzel F, Kunadt D, et al. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. J Hematol Oncol . May 13 2022;15(1):60. doi:10.1186/s13045-022-01267-7
6. Liu PI, Ishimaru T, McGregor DH, Okada H, Steer A. Autopsy study of granulocytic sarcoma (chloroma) in patients with myelogenous leukemia, Hiroshima-Nagasaki 1949-1969. Cancer . Apr 1973;31(4):948-55. doi:10.1002/1097-0142(197304)31:4<948::aid-cncr2820310428>3.0.co;2-n
7. Hazar V, Ozturk G, Yalcin K, et al. Different Kinetics and Risk Factors for Isolated Extramedullary Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Leukemia.Transplant Cell Ther . Oct 2021;27(10):859 e1-859 e10. doi:10.1016/j.jtct.2021.06.023
8. Hicsonmez G, Cetin M, Tuncer AM, et al. Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment. Leuk Res . Jan 2004;28(1):25-34. doi:10.1016/s0145-2126(03)00159-0
9. Bisschop MM, Revesz T, Bierings M, et al. Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukaemia. Leukemia . Jan 2001;15(1):46-9. doi:10.1038/sj.leu.2401971
10. Kobayashi R, Tawa A, Hanada R, et al. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.Pediatr Blood Cancer . Apr 2007;48(4):393-8. doi:10.1002/pbc.20824
11. Stove HK, Sandahl JD, Abrahamsson J, et al. Extramedullary leukemia in children with acute myeloid leukemia: A population-based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO).Pediatr Blood Cancer . Dec 2017;64(12)doi:10.1002/pbc.26520
12. Dusenbery KE, Howells WB, Arthur DC, et al. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children’s Cancer Group. J Pediatr Hematol Oncol . Oct 2003;25(10):760-8. doi:10.1097/00043426-200310000-00004
13. Schwyzer R, Sherman GG, Cohn RJ, Poole JE, Willem P. Granulocytic sarcoma in children with acute myeloblastic leukemia and t(8;21).Med Pediatr Oncol . Sep 1998;31(3):144-9. doi:10.1002/(sici)1096-911x(199809)31:3<144::aid-mpo3>3.0.co;2-b
14. Xin X, Zhu H, Chang Z, et al. Risk factors and prognosis analysis of acute myeloid leukemia in children. J BUON . Jan-Feb 2021;26(1):166-172.
15. Lee JW, Kim S, Jang PS, et al. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.J Pediatr Hematol Oncol . Apr 2020;42(3):e132-e139. doi:10.1097/MPH.0000000000001623
16. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children’s Oncology Group.Pediatr Blood Cancer . Apr 2012;58(4):519-24. doi:10.1002/pbc.23201
17. Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol . Sep 20 2014;32(27):3021-32. doi:10.1200/JCO.2014.55.3628
18. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Cancer . Feb 1 2012;118(3):761-9. doi:10.1002/cncr.26190
19. Kim EH, Im SA, Lee JW, Kim S, Cho B. Extramedullary Infiltration in Pediatric Acute Myeloid Leukemia on Surveillance Magnetic Resonance Imaging and its Relationship With Established Risk Factors. J Pediatr Hematol Oncol . Apr 1 2022;44(3):e713-e718. doi:10.1097/MPH.0000000000002353
20. Stolzel F, Luer T, Lock S, et al. The prevalence of extramedullary acute myeloid leukemia detected by (18)FDG-PET/CT: final results from the prospective PETAML trial. Haematologica . Jun 2020;105(6):1552-1558. doi:10.3324/haematol.2019.223032
21. Cribe AS, Steenhof M, Marcher CW, Petersen H, Frederiksen H, Friis LS. Extramedullary disease in patients with acute myeloid leukemia assessed by 18F-FDG PET. Eur J Haematol . Apr 2013;90(4):273-8. doi:10.1111/ejh.12085
22. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children’s Oncology Group study. Pediatr Blood Cancer . Sep 2010;55(3):414-20. doi:10.1002/pbc.22511
23. Pramanik R, Tyagi A, Chopra A, Kumar A, Vishnubhatla S, Bakhshi S. Myeloid Sarcoma Predicts Superior Outcome in Pediatric AML; Can Cytogenetics Solve the Puzzle? Clin Lymphoma Myeloma Leuk . Jun 2018;18(6):e249-e254. doi:10.1016/j.clml.2018.03.013
24. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol . Dec 20 2005;23(36):9172-8. doi:10.1200/JCO.2005.02.7482
25. Hu GH, Lu AD, Jia YP, Zuo YX, Wu J, Zhang LP. Prognostic Impact of Extramedullary Infiltration in Pediatric Low-risk Acute Myeloid Leukemia: A Retrospective Single-center Study Over 10 Years. Clin Lymphoma Myeloma Leuk . Nov 2020;20(11):e813-e820. doi:10.1016/j.clml.2020.06.009
26. Yoshihara S, Ando T, Ogawa H. Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: an easily overlooked but significant pattern of relapse. Biol Blood Marrow Transplant . Dec 2012;18(12):1800-7. doi:10.1016/j.bbmt.2012.05.010
27. Harris AC, Kitko CL, Couriel DR, et al. Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes.Haematologica . Feb 2013;98(2):179-84. doi:10.3324/haematol.2012.073189
28. Shem-Tov N, Saraceni F, Danylesko I, et al. Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse.Biol Blood Marrow Transplant . Jul 2017;23(7):1087-1094. doi:10.1016/j.bbmt.2017.03.023
29. Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplant . May 2002;29(10):843-52. doi:10.1038/sj.bmt.1703528
30. Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. Curr Opin Pediatr . Feb 2020;32(1):57-66. doi:10.1097/MOP.0000000000000855
31. Chevallier P, Mohty M, Lioure B, et al. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. J Clin Oncol . Oct 20 2008;26(30):4940-3. doi:10.1200/JCO.2007.15.6315
32. Xu LH, Wang Y, Chen ZY, Fang JP. Myeloid sarcoma is associated with poor clinical outcome in pediatric patients with acute myeloid leukemia.J Cancer Res Clin Oncol . Apr 2020;146(4):1011-1020. doi:10.1007/s00432-020-03128-7
33. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res . Jun 2001;7(6):1490-6.
34. Kharfan-Dabaja MA, Hamadani M, Reljic T, et al. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol . Nov 2013;163(3):315-25. doi:10.1111/bjh.12528
35. Owonikoko T, Agha M, Balassanian R, Smith R, Raptis A. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat Clin Pract Oncol . Aug 2007;4(8):491-5. doi:10.1038/ncponc0899
36. Sangle NA, Schmidt RL, Patel JL, et al. Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol . Aug 2014;27(8):1137-43. doi:10.1038/modpathol.2013.238
37. Kaur V, Swami A, Alapat D, et al. Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology . Jan 2018;23(1):17-24. doi:10.1080/10245332.2017.1333275